Now in EJOG: Marchand Institute Systematic Review on the Surgical Management of Interstitial (Cornual) Pregnancy

FOR IMMEDIATE RELEASE

MESA, Ariz. – October 10, 2026


The Marchand Institute for Minimally Invasive Surgery is pleased to announce the publication of our newest systematic review and meta-analysis in the European Journal of Obstetrics & Gynecology and Reproductive Biology (EJOG), one of the longest established journals in our specialty.

The paper, “Surgical management of interstitial (cornual) pregnancy: a systematic review of perioperative and reproductive outcomes with meta-analysis of hospital stay,” appears in Volume 327, December 2026, article 115472.

Read the Full Study

Free full text for 50 days (through November 28, 2026, no registration required): Elsevier Share Link
PubMed (NCBI): PMID 42854538
Official journal page: DOI 10.1016/j.ejogrb.2026.115472

Why Interstitial Pregnancy Matters

An interstitial pregnancy, often called a cornual pregnancy, implants in the segment of the fallopian tube that runs through the muscular wall of the uterus. It accounts for only a small fraction of ectopic pregnancies but a far larger share of the serious bleeding, because the surrounding myometrium allows the pregnancy to grow further before it ruptures. Management has moved steadily from laparotomy toward laparoscopic cornual resection and cornuostomy. What has not kept pace is the evidence. The literature is built largely from single case reports and small series, and the two questions patients ask most often after surgery, whether they can conceive again and whether the uterus will hold in a later pregnancy, are the ones that literature answers least well.

Study Design and Methodology

Our team searched PubMed/MEDLINE, Embase, Web of Science and CENTRAL through 5 July 2026, with additional screening of ClinicalTrials.gov and of reference lists. The protocol was prospectively registered with PROSPERO (CRD420261424165) and the review was reported to PRISMA standards. Screening and data extraction were carried out independently and in duplicate, with a third reviewer resolving any disagreement.

Screening identified 353 reports. Comparative pooling was restricted to data reported specifically for interstitial pregnancy, and reproductive outcomes were described separately rather than forced into a single pooled estimate.

Key Findings

  • Hospital stay. Two observational cohorts, 102 patients in total, could be pooled. Laparoscopy was associated with a stay 1.25 days shorter than laparotomy (95% CI -1.75 to -0.76 days, I² 0%). A modified Knapp-Hartung sensitivity interval of -4.47 to 1.96 days shows how much weight a two-study estimate can carry, and how little.
  • Other perioperative outcomes. Transfusion could not be pooled, because interstitial-specific counts were not available in one of the comparative cohorts. The evidence does not establish equivalence between the surgical routes on these outcomes.
  • Fertility. Populations, endpoints and denominators differed too much across reports to justify pooling. Raw conception counts in this literature cannot be read as a fertility rate.
  • Uterine rupture in later pregnancy. Subsequent ruptures are documented, including two in the broader Svenningsen cohort and events in other catalogued reports. The total number of treated cases is not a valid denominator for rupture risk, so the current literature cannot be used to reassure patients on this point.

Clinical Takeaways

Limited observational evidence points toward a shorter hospitalization after laparoscopy, which is consistent with what surgeons see in practice. The honest reading is that the estimate rests on two small cohorts and shifts considerably under a more conservative statistical model. Beyond length of stay, the published data do not support claims of equivalence between routes, and they do not provide a usable estimate of subsequent fertility or of uterine rupture risk.

“Interstitial pregnancy is managed laparoscopically in most centers now, and that is almost certainly the right direction,” said Greg J. Marchand, MD, FACS, FACOG, FICS, Director of the Marchand Institute for Minimally Invasive Surgery. “What our review shows is that the evidence base has not caught up with the practice. We can describe what was done, but we still cannot tell a woman her odds of carrying a later pregnancy safely. Closing that gap needs treatment-specific reporting of intention to conceive, subsequent pregnancies, and follow-up losses, not more case reports.”

Acknowledgements

We thank our research staff and contributing authors for their work on this project. This collaborative effort is essential for advancing the field of minimally invasive gynecologic surgery (MIGS) and improving care for women worldwide.

About the Marchand Institute

The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO and reported to PRISMA standards. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.

For more information on our surgical fellowships or to view our library of research, please visit MarchandInstitute.org.

Media Contact

Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com  |  (480) 999-0905

###

Follow Our Research

New peer-reviewed papers, meta-analyses and conference presentations in minimally invasive gynecologic surgery.

Book Appointment